CirculoGene Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 40

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $4.84M

  • Investors
  • 2

CirculoGene General Information

Description

Provider of molecular cancer diagnostics services intended to offer a non-invasive and cost-effective alternative for high-sensitivity monitoring across a variety of sample types. The company's services use minimal volumes of blood to provide unprecedented tumor monitoring information with an up-to-date clinical status in a complete, accurate, and timely manner, enabling physicians to detect known tumor-mutant DNA within cancer-associated genes present in diagnosed cancer patients.

Contact Information

Formerly Known As
CirculoGene Diagnostics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Diagnostic Equipment
Corporate Office
  • 3125 Independence Drive
  • Suite 301
  • Birmingham, AL 35209
  • United States
+1 (855) 000-0000

CirculoGene Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CirculoGene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 01-May-2023 $4.84M 000.00 Completed Generating Revenue
5. Debt - PPP 10-Apr-2020 00000 00.000 Completed Generating Revenue
4. Later Stage VC (Series C) 16-Sep-2019 00000 00.000 00.000 Completed Generating Revenue
3. Grant 17-Jun-2019 00.00 00.000 Completed Generating Revenue
2. Early Stage VC (Series B) 16-Nov-2018 $3.08M $5.06M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 06-Oct-2016 $1.98M $1.98M Completed Startup
To view CirculoGene’s complete valuation and funding history, request access »

CirculoGene Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series B-1 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A-1 6,945,058 $0.000100 $0.18 $0.18 1x $0.18 26.28%
Series A 5,143,500 $0.000100 $0.18 $0.18 1x $0.18 19.47%
To view CirculoGene’s complete cap table history, request access »

CirculoGene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Provider of molecular cancer diagnostics services intended to offer a non-invasive and cost-effective alternative for hi
Laboratory Services (Healthcare)
Birmingham, AL
40 As of 2023
000.00
0000000000 0 000.00

000000

velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupi
0000000000 000000000
Austin, TX
00 As of 0000
00000
000000000 00000

000000

incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nost
0000000000 000000000
San Diego, CA
00 As of 0000
000.00
0000 0000-00-00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CirculoGene Competitors (25)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aspira Women's Health Formerly VC-backed Austin, TX 00 00000 000000000 00000
Decipher Urologic Cancers Formerly VC-backed San Diego, CA 00 000.00 000000&0 000.00
Inivata Formerly VC-backed Cambridge, United Kingdom 00 00000 000000&0 00000
BioTheranostics Formerly VC-backed San Diego, CA 000 000.00 000000&0 000.00
Foundation Medicine Formerly VC-backed Cambridge, MA 0000 00000 00000000000
You’re viewing 5 of 25 competitors. Get the full list »

CirculoGene Patents

CirculoGene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021202766-B2 Method of preparing cell free nucleic acid molecules by in situ amplification Inactive 12-Aug-2015 000000000 0
AU-2016306688-A1 Method of preparing cell free nucleic acid molecules by in situ amplification Inactive 12-Aug-2015 000000000
EP-3757229-A1 Method of preparing cell free nucleic acid molecules by in situ amplification Pending 12-Aug-2015 000000000 0
US-11015213-B2 Method of preparing cell free nucleic acid molecules by in situ amplification Active 12-Aug-2015 000000000 00
US-20190024127-A1 Method of preparing cell free nucleic acid molecules by in situ amplification Active 12-Aug-2015 C12P19/34
To view CirculoGene’s complete patent history, request access »

CirculoGene Executive Team (12)

Name Title Board Seat Contact Info
Michael Mullen Co-Founder, Chairman, Chief Executive Officer & President
Louis Apicella Chief Technology Officer & Chief Operations Officer
Scott Rezek Co-Founder & Chief Administrative Officer
Travis Wold Chief Commercial Officer
Chen Yeh Ph.D Co-Founder
You’re viewing 5 of 12 executive team members. Get the full list »

CirculoGene Board Members (8)

Name Representing Role Since
Charles Clark CirculoGene Board Member 000 0000
Daniel Coleman CirculoGene Board Member 000 0000
Edwin Finch CirculoGene Board Member 000 0000
James Cantrell CirculoGene Board Member 000 0000
Richard Lanman MD Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

CirculoGene Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CirculoGene Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Keiretsu Forum Angel Group Minority 000 0000 000000 0
United States Department of Defense Government Minority 000 0000 000000 0
To view CirculoGene’s complete investors history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »